
Feb 2 (Reuters) - WAVE Life Sciences Ltd WVE.O:
WAVE LIFE SCIENCES ANNOUNCES PLANS TO ACCELERATE REGULATORY ENGAGEMENT WITH FULL CONTROL OF WVE-006 FOR ALPHA-1 ANTITRYPSIN DEFICIENCY
WAVE LIFE SCIENCES LTD: PLANS TO ENGAGE FDA ON POTENTIAL ACCELERATED APPROVAL PATHWAY FOR WVE-006, WITH REGULATORY FEEDBACK ANTICIPATED MID-2026
WAVE LIFE SCIENCES LTD - DATA FROM 400 MG COHORT ON TRACK FOR Q1 2026
WAVE LIFE SCIENCES LTD: DATA FROM 600 MG SINGLE AND MULTIDOSE COHORTS ARE EXPECTED IN 2026
WAVE LIFE SCIENCES LTD - EXPECTS CASH RUNWAY INTO THIRD QUARTER OF 2028